Manhai Gao1, Zhe Cui2, Dan Zhao2, Shurong Zhang3, Qiang Cai4. 1. Department of Anesthesia Surgery, The First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and Technology, Baotou, 014010, Inner Mongolia, China. 2. Department of Ophthalmology, The Third Affiliated Hospital of Qiqihar Medical University, Qiqihar, 161000, China. 3. Department of Ophthalmology, The Third Affiliated Hospital of Qiqihar Medical University, Qiqihar, 161000, China. 3263674202@qq.com. 4. Department of Anesthesia Surgery, The First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and Technology, Baotou, 014010, Inner Mongolia, China. libo00040130@sina.com.
Abstract
BACKGROUND: Retinoblastoma (RB) is the most prevalent primary intraocular malignancy, which commonly occurs during infant and childhood. OBJECTIVE: Our study aimed to investigate whether microRNA-9 (miR-9) could regulate RB cells and its mechanism. METHODS: qRT-PCR analysis was used to detect the expression of miR-9. In addition, to detect the migration of RB cells, wound healing assay was conducted. Xenograft tumor models in nude mice were also established, in order to assess the effects of miR-9 on tumor growth. qRT-PCR, luciferase reporter assay and western blot analysis were used to detect the target of miR-9. RESULTS: Initially, the expression level of miR-9 was significantly decreased in the RB tissues and blood samples from patients with RB. qRT-PCR, luciferase reporter assay and western blot analysis were used to confirm that PTEN was the target genes of miR-9 and it was negatively regulated by miR-9. When the expression of miR-9 was up-regulated, the cell viability, proliferation, migration and tumor formation were significantly suppressed. Furthermore, the expression level of PTEN was decreased after transfection of miR-9 mimic. Taken together, these results indicated that miR-9 might suppress the cell viability, proliferation, migration and tumor formation in RB by inhibiting PTEN. CONCLUSION: The in vitro and in vivo experiments demonstrated that miR-9 acts as a tumor suppressor function in RB cells and might serve as novel therapeutic targets for the treatment of RB.
BACKGROUND: Retinoblastoma (RB) is the most prevalent primary intraocular malignancy, which commonly occurs during infant and childhood. OBJECTIVE: Our study aimed to investigate whether microRNA-9 (miR-9) could regulate RB cells and its mechanism. METHODS: qRT-PCR analysis was used to detect the expression of miR-9. In addition, to detect the migration of RB cells, wound healing assay was conducted. Xenograft tumor models in nude mice were also established, in order to assess the effects of miR-9 on tumor growth. qRT-PCR, luciferase reporter assay and western blot analysis were used to detect the target of miR-9. RESULTS: Initially, the expression level of miR-9 was significantly decreased in the RB tissues and blood samples from patients with RB. qRT-PCR, luciferase reporter assay and western blot analysis were used to confirm that PTEN was the target genes of miR-9 and it was negatively regulated by miR-9. When the expression of miR-9 was up-regulated, the cell viability, proliferation, migration and tumor formation were significantly suppressed. Furthermore, the expression level of PTEN was decreased after transfection of miR-9 mimic. Taken together, these results indicated that miR-9 might suppress the cell viability, proliferation, migration and tumor formation in RB by inhibiting PTEN. CONCLUSION: The in vitro and in vivo experiments demonstrated that miR-9 acts as a tumor suppressor function in RB cells and might serve as novel therapeutic targets for the treatment of RB.
Authors: Helen Dimaras; Kahaki Kimani; Elizabeth A O Dimba; Peggy Gronsdahl; Abby White; Helen S L Chan; Brenda L Gallie Journal: Lancet Date: 2012-03-12 Impact factor: 79.321
Authors: Ivna Néria Silva Ribamar Carvalho; Adriana Helena de Oliveira Reis; Pedro H Cabello; Fernando Regla Vargas Journal: Carcinogenesis Date: 2013-09-17 Impact factor: 4.944
Authors: E A Braga; V I Loginov; E A Filippova; A M Burdennyi; I V Pronina; T P Kazubskaya; D S Khodyrev; D O Utkin; D N Kushlinskii; L V Adamyan; N E Kuslinskii Journal: Bull Exp Biol Med Date: 2018-11-28 Impact factor: 0.804